US FDA approves Bristol Myers' schizophrenia drug
Shares up about 4% in extended trading
FDA approval for new type of schizophrenia treatment
Bristol prices drug at $1,850 a month
Adds shares in paragraph 4, pricing details in paragraph 5 and company comments in paragraphs 10-11
By Bhanvi Satija and Michael Erman
Sept 26 (Reuters) -The U.S. FDA approved Bristol Myers Squibb's BMY.N schizophrenia drug on Thursday, providing patients with a treatment option that reduces symptoms of the mental disorder without common side effects.
Bristol Myers obtained the drug Cobenfy, also known as KarXT, through its $14 billion takeover of Karuna Therapeutics last year. The drugmaker is banking on the treatment to help power growth as patents on its older cancer drug Revlimid and blood thinner Eliquis expire later this decade.
William Blair analysts expect $2.5 billion in U.S. sales for the drug by 2030. Bristol shares rose 4% in extended trading.
Bristol said it expects to make the drug available to patients by late October, at a list price of $1,850 a month or about $22,500 annually.
FDA's approval was based on data from two studies in which patients on the drug experienced a meaningful reduction in symptoms. The drug is the first approved antipsychotic that targets cholinergic receptors as opposed to dopamine receptors, which have long been the standard of care.
"So there is an unmet need still in the treatment of schizophrenia, particularly in patients who may show response to the positive symptoms but still have residual negative symptoms," said Alan Schatzberg, psychiatry professor at Stanford University School of Medicine.
Schatzberg said the drug could be a "game changer" for schizophrenia patients.
While antipsychotics that target dopamine receptors reduce symptoms of the disorder, their use also causes side effects such as tremors or involuntary movements and sleepiness.
Common side effects from Cobenfy in trials included vomiting, nausea, constipation among others. The FDA said Cobenfy should not be prescribed to patients with urinary retention, or those with moderate or severe kidney or liver disease.
Bristol expects 80% of the drug's patient population to be covered under Medicare and Medicaid insurance plans in the 12 to 18 months of its launch.
"Our focus is to ensure that all of these coverage decisions are made very quickly after launch, so we can have access for patients," said Chief Commercialization Officer Adam Lenkowsky.
The company expected to see significant utilization of the drug by the end of 2025, he added.
Currently approved antipsychotic drugs include Vanda Pharmaceuticals' VNDA.O Fanapt, AbbVie's ABBV.N Vraylar and generic drugs like olanzapine, quetiapine and aripiprazole, among others.
AbbVie is also developing newer drugs for the disease after its $8.7 billion takeover of Cerevel Therapeutics late last year. Reviva Pharmaceuticals RVPH.O, Neurocrine Biosciences NBIX.O and Celon Pharma CLNP.WA are also developing treatments for schizophrenia.
Schizophrenia causes persistent delusions and hallucinations and significantly impairs the way patients perceive reality.
Reporting by Puyaan Singh and Bhanvi Satija in Bengaluru and Michael Erman in New York; Editing by Krishna Chandra Eluri and Alan Barona
Últimas notícias
Isenção de Responsabilidade: As entidades do XM Group proporcionam serviço de apenas-execução e acesso à nossa plataforma online de negociação, permitindo a visualização e/ou uso do conteúdo disponível no website ou através deste, o que não se destina a alterar ou a expandir o supracitado. Tal acesso e uso estão sempre sujeitos a: (i) Termos e Condições; (ii) Avisos de Risco; e (iii) Termos de Responsabilidade. Este, é desta forma, fornecido como informação generalizada. Particularmente, por favor esteja ciente que os conteúdos da nossa plataforma online de negociação não constituem solicitação ou oferta para iniciar qualquer transação nos mercados financeiros. Negociar em qualquer mercado financeiro envolve um nível de risco significativo de perda do capital.
Todo o material publicado na nossa plataforma de negociação online tem apenas objetivos educacionais/informativos e não contém — e não deve ser considerado conter — conselhos e recomendações financeiras, de negociação ou fiscalidade de investimentos, registo de preços de negociação, oferta e solicitação de transação em qualquer instrumento financeiro ou promoção financeira não solicitada direcionadas a si.
Qual conteúdo obtido por uma terceira parte, assim como o conteúdo preparado pela XM, tais como, opiniões, pesquisa, análises, preços, outra informação ou links para websites de terceiras partes contidos neste website são prestados "no estado em que se encontram", como um comentário de mercado generalizado e não constitui conselho de investimento. Na medida em que qualquer conteúdo é construído como pesquisa de investimento, deve considerar e aceitar que este não tem como objetivo e nem foi preparado de acordo com os requisitos legais concebidos para promover a independência da pesquisa de investimento, desta forma, deve ser considerado material de marketing sob as leis e regulações relevantes. Por favor, certifique-se que leu e compreendeu a nossa Notificação sobre Pesquisa de Investimento não-independente e o Aviso de Risco, relativos à informação supracitada, os quais podem ser acedidos aqui.
